Table 1.
Characteristics of patients in the exercise and control groups
| Exercise | Control | |
|---|---|---|
| n | 27 | 28 |
| Age, yr (means ± SD) | 58.8 ± 5.3 | 60.8 ± 5.8 |
| Body mass index, kg/m² (mean ± SD) | 28.0 ± 8.0 | 27.1 ± 4.4 |
| Disease duration, yr (mean ± SD) | 28.6 ± 10.7 | 28.5 ± 11.0 |
| Sex, n (Male/Female) | 20/7 | 20/8 |
| Disease, n (%) | ||
| Ankylosing spondylitis | 20 (74) | 20 (71.4) |
| Psoriatic arthritis | 7 (26) | 8 (28.6) |
| Treatment, n (%) | ||
| Biological therapy* | 10 (37.0) | 19 (67.8) |
| Immunosuppressants | 4 (15.0) | 4 (14.2) |
| Prednisone | 4 (15.0) | 1 (3.5) |
| Comorbidities, n (%) | ||
| Arterial hypertension | 20 (74.0) | 14 (50.0) |
| Diabetes mellitus | 5 (19.0) | 11 (39.2) |
| Chronic renal disease | 2 (7.0) | 2 (7.1) |
| IgG positivity, n (%) | 16 (59.0) | 16 (57.1) |
| NAb positivity, n (%) | 10 (37.0) | 12 (42.8) |
| Physically inactive patients, n (%)Ϯ | 14 (51.8) | 10 (37.0) |
*Biological therapy: TNF inhibitor (exercise n = 4; control n = 16), monoclonal antibodies (exercise n = 10; control n = 17), etanercept (exercise n = 0; control n = 4), adalimumab (exercise n = 3; control n = 7), infliximab (exercise n = 1; control n = 5), certolizumab pegol (exercise n = 1; control n = 0); immunosuppressants: leflunomide (exercise n = 4; control n = 3), cyclosporin (exercise n = 1; control n = 0). Sums to more than the patient numbers provided because some patients were taking more than one biological agent.
ϮOne missing data in the control group.